Immix Biopharma, Inc. Announces Results of 2026 Annual Shareholder Meeting

Immix Biopharma, Inc. (NASDAQ: IMMX) has released its Form 8-K reporting the results of the 2026 Annual Meeting of Stockholders held on May 22, 2026 in Los Angeles, California.

Key Points from the Report

• Date of Meeting: May 22, 2026
• Location: Los Angeles, California
• Form Filed: 8-K Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
• Trading Symbol: IMMX
• Exchange: The Nasdaq Stock Market LLC
• Emerging Growth Company: Yes

Shareholder Proposals Voted Upon

At the Annual Meeting, shareholders voted on two critical proposals:

1. Election of Directors:
   • Ilya Rachman was elected as a director.
   • Voting Results:
     • For: 35,738,887 shares
     • Withheld: 121,893 shares
     • Broker Non-Votes: 6,445,683 shares
   • The strong approval rate (over 99% of votes cast in favor) reflects broad shareholder support for the current leadership.
2. Ratification of Auditors:
   • Crowe LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
   • The ratification of Crowe LLP maintains continuity in financial oversight and may be seen as a positive for investors seeking stability and transparency in financial reporting.
   • Voting results were overwhelmingly in favor, with no material opposition or abstentions noted.

Other Disclosures

• Immix Biopharma confirmed its status as an Emerging Growth Company under SEC rules, which allows the company to take advantage of certain regulatory exemptions.
• The company did not elect to use the extended transition period for complying with new or revised financial accounting standards, meaning it will adopt new standards on the same timeline as other public companies.

Potentially Price-Sensitive Information for Shareholders

• The confirmation of leadership and auditor stability is generally supportive for share value as it signals management continuity and robust financial controls.
• No material changes or amendments to previously-filed reports were disclosed.
• No written communications, soliciting material, or pre-commencement tender offers were reported in connection with the meeting, indicating no pending merger, acquisition, or similar corporate actions at this time.

Conclusion

The 2026 Annual Meeting results confirm Immix Biopharma’s ongoing commitment to governance and financial transparency. With the election of Ilya Rachman and the ratification of Crowe LLP as auditor, the company maintains stability in its leadership and oversight. As no material changes, mergers, or acquisitions were reported, the news is neutral to slightly positive for shareholders, given the continued support of management and auditors.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Readers are encouraged to conduct their own research or consult with a financial advisor before making any investment decisions. Immix Biopharma’s filings and corporate actions may have price-sensitive implications; however, there were no extraordinary events disclosed in this report that would warrant immediate action. The information contained herein is based on filings made with the SEC as of May 22, 2026.

View Immix Biopharma, Inc. Historical chart here